Healthcare provider profile · identity verified

Pamela Ross

Internal Medicine · LEWISTON, ME · NPI 1144200833

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	594	162
Levothyroxine Sodium	Levothyroxine Sodium	435	113
Amlodipine Besylate	Amlodipine Besylate	382	110
Losartan Potassium	Losartan Potassium	320	91
Sertraline Hcl	Sertraline Hcl	309	80
Rosuvastatin Calcium	Rosuvastatin Calcium	305	79
Omeprazole	Omeprazole	292	89
Lisinopril	Lisinopril	274	82
Metoprolol Succinate	Metoprolol Succinate	248	73
Hydrochlorothiazide	Hydrochlorothiazide	240	76
Gabapentin	Gabapentin	200	61
Potassium Chloride	Potassium Chloride	152	47
Pantoprazole Sodium	Pantoprazole Sodium	139	44
Furosemide	Furosemide	138	47
Trazodone Hcl	Trazodone Hcl	135	32
Albuterol Sulfate Hfa	Albuterol Sulfate	132	55
Simvastatin	Simvastatin	132	37
Metformin Hcl	Metformin Hcl	120	37
Duloxetine Hcl	Duloxetine Hcl	114	26
Famotidine	Famotidine	108	30
Fluticasone Propionate	Fluticasone Propionate	103	37
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	100	18
Alendronate Sodium	Alendronate Sodium	99	31
Pravastatin Sodium	Pravastatin Sodium	82	23
Bupropion Xl	Bupropion Hcl	71	21
Ozempic	Semaglutide	69	16
Ezetimibe	Ezetimibe	64	20
Clopidogrel	Clopidogrel Bisulfate	61	17
Glipizide	Glipizide	61	17
Allopurinol	Allopurinol	58	17
Tramadol Hcl	Tramadol Hcl	57	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	56	24
Venlafaxine Hcl Er	Venlafaxine Hcl	54	12
Montelukast Sodium	Montelukast Sodium	51	14
Metoprolol Tartrate	Metoprolol Tartrate	50	17
Tamsulosin Hcl	Tamsulosin Hcl	50	17
Ropinirole Hcl	Ropinirole Hcl	49	15
Zolpidem Tartrate	Zolpidem Tartrate	48	17
Mirtazapine	Mirtazapine	46	13
Eliquis	Apixaban	45	16
Olmesartan Medoxomil	Olmesartan Medoxomil	44	13
Atenolol	Atenolol	42	13
Hydralazine Hcl	Hydralazine Hcl	42	12
Advair Hfa	Fluticasone Propion/Salmeterol	40	11
Carvedilol	Carvedilol	40	12
Spironolactone	Spironolactone	40	13
Escitalopram Oxalate	Escitalopram Oxalate	39	13
Azelastine Hcl	Azelastine Hcl	37	11
Donepezil Hcl	Donepezil Hcl	37	suppressed
Xarelto	Rivaroxaban	36	suppressed
Jardiance	Empagliflozin	35	suppressed
Synthroid	Levothyroxine Sodium	34	suppressed
Oxycodone Hcl	Oxycodone Hcl	33	suppressed
Prednisone	Prednisone	33	28
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	32	13
Myrbetriq	Mirabegron	32	suppressed
Meclizine Hcl	Meclizine Hcl	31	17
Estradiol	Estradiol	30	16
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	30	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	29	11
Paroxetine Hcl	Paroxetine Hcl	27	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	26	suppressed
Valacyclovir	Valacyclovir Hcl	25	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	24	suppressed
Metformin Hcl Er	Metformin Hcl	24	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	23	suppressed
Tradjenta	Linagliptin	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	22	13
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	21	21
Arnuity Ellipta	Fluticasone Furoate	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	21	suppressed
Incruse Ellipta	Umeclidinium Bromide	20	suppressed
Fluconazole	Fluconazole	19	suppressed
Symbicort	Budesonide/Formoterol Fumarate	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Clotrimazole	Clotrimazole	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	18	suppressed
Benazepril Hcl	Benazepril Hcl	17	suppressed
Divalproex Sodium	Divalproex Sodium	17	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Ondansetron Hcl	Ondansetron Hcl	17	suppressed
Topiramate	Topiramate	17	suppressed
Clonazepam	Clonazepam	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Tizanidine Hcl	Tizanidine Hcl	16	suppressed
Levetiracetam	Levetiracetam	15	suppressed
Mounjaro	Tirzepatide	15	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	15	suppressed
Varenicline Tartrate	Varenicline Tartrate	15	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	14	14
Buspirone Hcl	Buspirone Hcl	14	suppressed
Celecoxib	Celecoxib	14	suppressed
Januvia	Sitagliptin Phosphate	14	suppressed
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	13	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	13	suppressed
Ipratropium Bromide	Ipratropium Bromide	13	suppressed
Meloxicam	Meloxicam	13	suppressed
Nitroglycerin	Nitroglycerin	13	11
Risperidone	Risperidone	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Trulicity	Dulaglutide	13	suppressed
Valsartan	Valsartan	13	suppressed
Divalproex Sodium Er	Divalproex Sodium	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Lorazepam	Lorazepam	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Colchicine	Colchicine	11	suppressed
Creon	Lipase/Protease/Amylase	11	suppressed
Farxiga	Dapagliflozin Propanediol	11	suppressed
Finasteride	Finasteride	11	suppressed
Glipizide Er	Glipizide	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error